Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Muik

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Science Immunology|June 2, 2022
Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopesJasmin Quandt, Alexander Muik, Nadine Salisch, et al.
Science (New York, N.Y.)|January 18, 2022
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human seraAlexander Muik, Bonny Gaby Lui, Ann-Kathrin Wallisch, et al.
Cell Reports|August 1, 2023
Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunityAlexander Muik, Bonny Gaby Lui, Jasmin Quandt, et al.
Nature Medicine|April 23, 2021
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 studyJingxin Li, Aimin Hui, Xiang Zhang, et al.
NPJ Vaccines|January 13, 2026
Strong and early immune responses against SARS-CoV-2 in mice and rhesus macaques after BNT162b3 vaccinationAnnette B Vogel, Bonny G Lui, Kristin Tompkins, et al.
Oncoimmunology|February 21, 2022
An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulationAlexander Muik, Isil Altintas, Friederike Gieseke, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activityAlexander Muik, Homer C Adams 3rd, Friederike Gieseke, et al.
Scientific Reports|July 24, 2025
A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockadeIşıl Altıntaş, Kristina B Nürmberger, Andrea Imle, et al.
NPJ Vaccines|July 6, 2026
Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccineChaitanya Kurhade, Wei Chen, Weiqiang Li, et al.
Journal for Immunotherapy of Cancer|April 11, 2025
Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effectsMichela Capello, Angelica Sette, Theo Plantinga, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Science Immunology|June 2, 2022
Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopesJasmin Quandt, Alexander Muik, Nadine Salisch, et al.
Science (New York, N.Y.)|January 18, 2022
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human seraAlexander Muik, Bonny Gaby Lui, Ann-Kathrin Wallisch, et al.
Cell Reports|August 1, 2023
Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunityAlexander Muik, Bonny Gaby Lui, Jasmin Quandt, et al.
Nature Medicine|April 23, 2021
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 studyJingxin Li, Aimin Hui, Xiang Zhang, et al.
NPJ Vaccines|January 13, 2026
Strong and early immune responses against SARS-CoV-2 in mice and rhesus macaques after BNT162b3 vaccinationAnnette B Vogel, Bonny G Lui, Kristin Tompkins, et al.
Oncoimmunology|February 21, 2022
An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulationAlexander Muik, Isil Altintas, Friederike Gieseke, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activityAlexander Muik, Homer C Adams 3rd, Friederike Gieseke, et al.
Scientific Reports|July 24, 2025
A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockadeIşıl Altıntaş, Kristina B Nürmberger, Andrea Imle, et al.
NPJ Vaccines|July 6, 2026
Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccineChaitanya Kurhade, Wei Chen, Weiqiang Li, et al.
Journal for Immunotherapy of Cancer|April 11, 2025
Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effectsMichela Capello, Angelica Sette, Theo Plantinga, et al.
Pageof 5